%0 Journal Article %T Beyond CAR T cells: Engineered Vγ9Vδ2 T cells to fight solid tumors %+ Immunobiology of Human αβ and γδ T Cells and Immunotherapeutic Applications (CRCINA-ÉQUIPE 1) %+ LabEX IGO Immunothérapie Grand Ouest %+ ImCheck Therapeutics [Marseille] %A Rafia, Chirine %A Harly, Christelle %A Scotet, Emmanuel %< avec comité de lecture %@ 0105-2896 %J Immunological Reviews %I Wiley %V 298 %N 1 %P 117-133 %8 2020-11 %D 2020 %R 10.1111/imr.12920 %M 32965719 %Z Life Sciences [q-bio]/CancerJournal articles %X Despite recent significant progress in cancer immunotherapies based on adoptive cell transfer(s)(ACT), the eradication of cancers still represents a major clinical challenge. In particular, the efficacy of current ACT-based therapies against solid tumors is dramatically reduced by physical barriers that prevent tumor infiltration of adoptively transferred effectors, and the tumor environment that suppress their anti-tumor functions. Novel immunotherapeutic strategies are thus needed to circumvent these issues. Human peripheral blood Vγ9Vδ2 T cells, a non-alloreactive innate-like T lymphocyte subset, recently proved to be a promising anti-tumor effector subset for ACT-based immunotherapies. Furthermore, new cell engineering tools that leverage the potential of CRISPR/Cas technology open astounding opportunities to optimize their anti-tumor effector functions. In this review, we present the current ACT strategies based on engineered T cells and their limitations. We then discuss the potential of engineered Vγ9Vδ2 T cell to overcome these limitations and improve ACT-based cancer immunotherapies. %G English %L inserm-03496227 %U https://inserm.hal.science/inserm-03496227 %~ INSERM %~ UNIV-NANTES %~ CNRS %~ UNIV-ANGERS %~ CRCINA %~ TEST-HALCNRS %~ NANTES-UNIVERSITE %~ UNIV-NANTES-AV2022 %~ FRM